Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
UBF CRISPR/Cas9 KO Plasmid (h): sc-400521
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- UBF CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the UBF genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: UBF Antibody (F-9): sc-13125
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
UBF CRISPR/Cas9 KO Plasmid (h) | sc-400521 | 20 µg | $397.00 |
Overview
UBTF encodes upstream binding transcription factor (UBF), a high-mobility group (HMG) box DNA-binding protein that is essential for RNA polymerase I–dependent transcription of ribosomal DNA. UBF helps organize rDNA chromatin, promotes formation of the Pol I preinitiation complex, and supports nucleolar structure and ribosome biogenesis, thereby linking it to cellular growth control and proteostasis. Through its role in nucleolar stress signaling and coordination with cell-cycle and DNA damage response pathways, altered UBTF/UBF activity can influence proliferation and genome stability. Dysregulation of Pol I transcription and nucleolar function is a recurrent feature of cancer biology and has also been implicated in neurodevelopmental and neurodegenerative disease contexts.
UBF CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the UBTF gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the UBTF together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the UBTF open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish UBF protein expression.
This CRISPR knockout system enables efficient generation of UBTF-deficient cell models for investigation of UBF signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting UBTF exon(s) critical for UBF function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple UBTF genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by UBF CRISPR/Cas9 KO Plasmid (h) and UBF CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the UBTF locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by UBF HDR Plasmid (h) and UBF HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by UBTF homology arms to support homology-directed repair at defined UBTF target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.